FDA Approves GlaxoSmithKline's Nucala For Children Ages 6-11 With Severe Eosinophilic Asthma
September 12 2019 - 3:42PM
Dow Jones News
By Maria Armental
GlaxoSmithKline PLC's Nucala has been approved in the U.S. as an
add-on treatment for children 6 to 11 years old with a severe type
of asthma characterized by high levels of white blood cells, the
company said Thursday.
Nucala, which contains the active substance mepolizumab, was
first approved by the Food and Drug Administration in 2015 as an
add-on maintenance treatment for patients with severe eosinophilic
asthma at least 12 years old. It has been approved in the European
Union for use as an add-on treatment for severe eosinophilic asthma
in patients aged 6 and older since August 2018.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
September 12, 2019 16:27 ET (20:27 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024